Abstract
Various studies have documented a rapid onset of efficacy in migraine prevention for monoclonal antibodies targeting CGRP. Aim of the present study was to assess migraine outcome following the first 4 weeks of treatment in patients treated with erenumab 70 mg or galcanezumab 240 mg (loading dose).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
